The SEC has announced settled charges against New Jersey medical technologies company Becton Dickinson (BD), alleging that it failed to inform investors about the FDA approval status of its Alaris infusion pump, an electronic device that delivers IV fluids and medications at controlled doses.
The agency also stated that BD
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day